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Different species exposed to a common stress may adapt by mutations
in shared pathways or in unique systems, depending on how past environments
have molded their genomes. Understanding how diverse bacterial pathogens evolve
in response to an antimicrobial treatment is a pressing example of this problem,
where discovery of molecular parallelism could lead to clinically useful predictions.
Evolution experiments with pathogens in environments containing antibiotics, combined with periodic whole-population genome sequencing, can be used to identify
many contending routes to antimicrobial resistance. We separately propagated two
clinically relevant Gram-negative pathogens, Pseudomonas aeruginosa and Acinetobacter baumannii, in increasing concentrations of tobramycin in two different environments each: planktonic and bioﬁlm. Independently of the pathogen, the populations adapted to tobramycin selection by parallel evolution of mutations in fusA1,
encoding elongation factor G, and ptsP, encoding phosphoenolpyruvate phosphotransferase. As neither gene is a direct target of this aminoglycoside, mutations to
either are unexpected and underreported causes of resistance. Additionally, both
species acquired antibiotic resistance-associated mutations that were more prevalent
in the bioﬁlm lifestyle than in the planktonic lifestyle; these mutations were in electron transport chain components in A. baumannii and lipopolysaccharide biosynthesis enzymes in P. aeruginosa populations. Using existing databases, we discovered
site-speciﬁc parallelism of fusA1 mutations that extends across bacterial phyla and
clinical isolates. This study suggests that strong selective pressures, such as antibiotic treatment, may result in high levels of predictability in molecular targets
of evolution, despite differences between organisms’ genetic backgrounds and
environments.
IMPORTANCE The rise of antimicrobial resistance is a leading medical threat, moti-

vating efforts to forecast both its evolutionary dynamics and its genetic causes. Aminoglycosides are a major class of antibiotics that disrupt translation, but resistance
may occur by a number of mechanisms. Here, we show the repeated evolution of
resistance to the aminoglycoside tobramycin in both P. aeruginosa and A. baumannii
via mutations in fusA1, encoding elongation factor G, and ptsP, encoding the
nitrogen-speciﬁc phosphotransferase system. Laboratory evolution and wholepopulation genome sequencing were used to identify these targets, but mutations
at identical amino acid positions were also found in published genomes of diverse
bacterial species and clinical isolates. We also identiﬁed other resistance mechanisms
associated with growth in bioﬁlms that likely interfere with drug binding or uptake.
Characterizing the evolution of multiple species in the presence of antibiotics can
identify new, repeatable causes of resistance that may be predicted and counteracted by alternative treatment.
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evolution, population genetics
he notion that evolution can be forecasted at the level of phenotype, gene, or even
amino acid is no longer a fantasy in the postgenomic era (1). Most forecasting
efforts rely on history to anticipate the future, and the explosive growth of wholegenome sequencing (WGS) now sets the stage to resolve evolutionary phenomena in
action and determine the probabilities of the next selected path. Among the best
examples, analysis by WGS of bacterial populations exposed to strong selection, like
antibiotics, will likely identify genotypes that produce resistance and increased ﬁtness
(2–6). Repeated instances of selection with the same antibiotic may enrich the same
types of mutations and, ultimately, enable some measure of predictability (7, 8). For
instance, we can be conﬁdent that exposing different bacteria to high doses of
ﬂuoroquinolones, like ciproﬂoxacin, selects for substitutions in residue 83 or 87 of the
drug target, DNA gyrase A (9, 10). Furthermore, drug resistance phenotypes have been
predicted from genome sequence data for certain bacterial species (11, 12). These
successful predictions likely result from an underlying genetic constraint, where relatively few single mutations can achieve high-level resistance, as well as population
genetic power, where strong selection acts on populations with an ample mutation
supply (7).
Yet predicting evolution may be hampered when these conditions are not met or
when antibiotic selection produces species- or environment-speciﬁc outcomes. Evolution experiments in environments containing antibiotics have demonstrated that subjecting different bacterial strains to the same antibiotic treatment regime (13–15) or the
same strains to different environments (2, 16) can select for different drug resistance
levels as well as molecular targets. We can test the potential for predicting the evolved
levels and genetic causes of drug resistance by studying the evolution of resistance in
different environments and across different species with inherently different genetic
backgrounds.
Acinetobacter baumannii and Pseudomonas aeruginosa are ESKAPE (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens that are responsible for
multidrug-resistant infections (17). These species are members of the Moraxellaceae
and Pseudomonadeae families, respectively, and the genomes of the species differ in
size by approximately 2.7 Mb, or more than 40%. Infections with these two opportunistic pathogens are often associated with a bioﬁlm mode of growth (18, 19), where the
bacteria grow in aggregates on surfaces and are protected from antimicrobials by a
number of mechanisms. This bioﬁlm protection may occur from secreted substances,
like polysaccharides, proteins, or environmental DNA, that limit diffusion or by slowing
growth and rendering the bacteria much less susceptible to an antibiotic (20, 21). Given
the lifestyle differences between cells growing in a bioﬁlm and free-living cells, we
asked whether the evolution of tobramycin (TOB) resistance could proceed by different
mechanisms between these two environments. TOB is an aminoglycoside antibiotic
commonly used to treat infections caused by Gram-negative pathogens. Aminoglycosides are actively transported into the cell following binding to the outer membrane
and can subsequently cause cell death by binding the ribosome and disrupting
translation (22, 23). Resistance to aminoglycosides can occur by several mechanisms,
including alteration of the translation machinery, reduced uptake, increased drug
efﬂux, and enzymatic inactivation of the drug (24–26). However, the prevalence of
these resistance strategies in different environments is incompletely understood.
Here, we experimentally propagated two bacterial species from different families, A.
baumannii and P. aeruginosa, in increasing concentrations of the aminoglycoside TOB
in both planktonic and bioﬁlm environments. We performed whole-population genome sequencing at regular intervals for each lineage to identify the range of molecular mechanisms of resistance available in these species and environments. FurtherMay/June 2020 Volume 11 Issue 3 e00932-20
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RESULTS
We used TOB-sensitive ancestral clones A. baumannii ATCC 17978 and P. aeruginosa
strain UCBPP-PA14 (PA14) to inoculate ﬁve replicate, single-species lineages for each of
four treatments: planktonic growth without drug, planktonic growth with drug, bioﬁlm
growth without drug, and bioﬁlm growth with drug. The evolution experiment was
performed using a previously described protocol in which planktonic populations were
propagated through a 1:100 dilution into fresh medium every 24 h and bioﬁlm populations were propagated through the transfer of a colonized 7-mm polystyrene bead
(16, 29, 30). This produces similar transfer sizes for both the planktonic and bioﬁlm
treatments: approximately 1 ⫻ 107 CFU/transfer for A. baumannii and 2 ⫻ 108 CFU/
transfer for P. aeruginosa. Populations undergo approximately 6.64 generations/day,
producing at least an estimated 106 new mutations each day (3, 16). Populations were
initially exposed to 0.5⫻ MIC, and the antibiotic concentrations were subsequently
doubled every 72 h. We propagated the populations for 12 days and periodically froze
samples for later sequencing and phenotypic analysis. The experimental design is
illustrated in Fig. 1A and B.
Parallel evolution of TOB resistance phenotypes and genotypes. For a population to survive to the end of the experiment, it must evolve resistance to at least four
times the TOB concentration that would kill the ancestral clone. Previous evolution
experiments in the presence of antibiotics showed that replicate populations may
acquire different levels of resistance in response to the same antibiotic treatment
regime when evolving in different environments (13, 16, 31). While the resistance levels
did not change during the experiment for populations not exposed to antibiotics,
populations propagated under TOB selection demonstrated 8⫻ to 32⫻ the MIC of the
ancestral clone (Fig. 1C). These gains in resistance correspond to an increase from
sensitive to intermediate or resistant according to Clinical and Laboratory Standards
Institute (CLSI) breakpoints (32).
Prior mutant screens have indicated that mutations in as many as 135 genes can
produce low-level resistance to aminoglycosides, suggesting that TOB resistance may
arise by mutations in diverse molecular targets (33). Instead, whole-genome sequencing of the 20 TOB-treated populations at day 12 revealed that mutations in only a few
loci rose to high frequencies (Fig. 2; see also Fig. S2 in the supplemental material). The
large effective population sizes (⬎107 CFU) of these experiments ensured that mutations occurred in nearly every position across the genome and often occurred multiple
times (3, 16). Further, the large sizes of these populations, despite strong drug selection,
greatly empowers selection relative to the effects of drift or mutation pressure (3, 34).
Therefore, mutations identiﬁed by population-wide WGS, which, in our case, reliably
detects those occurring at a ⱖ5% frequency, represent the ﬁttest resistant genotypes
among many contenders. Mutations in the same genes selected in parallel across
antibiotic-treated populations (Fig. 2) provide clear evidence of their ﬁtness beneﬁts in
the presence of TOB, and their absence in drug-free populations indicates that they
were not simply selected by other experimental conditions (Fig. S2). In the unlikely
possibility that these particular loci experienced signiﬁcantly higher mutation rates in
the presence of TOB, only selection would have driven them to these frequencies
within 3 to 12 days (3).
May/June 2020 Volume 11 Issue 3 e00932-20
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more, we aimed to examine the evolutionary dynamics of adaptation—what mutations
are favored at each drug concentration in each environment—in the presence of TOB.
The success of the available molecular mechanisms of resistance is determined by the
order in which causative mutations occur (26), the ﬁtness imposed by those mechanisms at a given drug concentration in the selective environment (27), and the
combinations of these mutations that are selectively tolerated (28). This study depicts
both marked gene- and even domain-level parallelism in the evolved genotypes as well
as genetic differences between lifestyles that indicate shifts in the mode of action of
TOB with potentially important clinical consequences.
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Despite the many differences between A. baumannii and P. aeruginosa, both species
frequently acquired mutations in fusA1 and ptsP (Fig. 2). The fusA1 gene encodes
elongation factor G (EF-G), an essential protein which functions in catalyzing translocation and ribosome recycling during translation (35). While A. baumannii has one copy
of fusA1, P. aeruginosa and other Pseudomonas species also encode the paralogous
gene fusA2 (36). Mutations to EF-G have received little attention as a mechanism of TOB
resistance in P. aeruginosa, and there are no previous reports of mutations to EF-G
being a mechanism of TOB resistance in A. baumannii, to the best of our knowledge (24,
37). EF-G is also not known to be a binding target of TOB; however, this protein is the
direct binding target of other antibiotics, including fusidic acid and argyrin B (38, 39).
The exact mechanism by which mutations in EF-G confer aminoglycoside resistance is
currently unknown, but this study demonstrates that it is an important resistance
determinant. The ptsP gene encodes the phosphoenolpyruvate phosphotransferase
protein, which is part of the nitrogen phosphotransferase system and which has been
identiﬁed to be a target of TOB resistance for P. aeruginosa but not for A. baumannii,
to the best of our knowledge (33, 37). The mechanism by which mutations in ptsP
confer resistance to TOB is also unknown. However, the nitrogen phosphotransferase
system has been shown to regulate the GigA and GigB pathway, which functions in
coordinating the antibiotic stress response, suggesting a link between the nitrogen
phosphotransferase system and coordination of the transcriptional response to antibiotic pressure (40). Therefore, even though mutations in as many as 135 genes confer
reduced susceptibility, mutations in two genes, fusA1 and ptsP, appear to confer the
greatest ﬁtness advantages in the presence of TOB across species and environments.
May/June 2020 Volume 11 Issue 3 e00932-20
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FIG 1 Parallel evolution of tobramycin resistance level across species and environments. Populations of
A. baumannii and P. aeruginosa were propagated in minimal medium with either increasing concentrations of tobramycin or no drug and in either a planktonic or a bioﬁlm lifestyle. Five replicate populations
were propagated per treatment. (A) Populations were either propagated for 12 days in no antibiotic or
inoculated into half the MIC of tobramycin, with the concentrations being doubled every 72 h. Samples
of each population were archived for later phenotypic analysis and sequencing periodically throughout
the experiment (red arrows). (B) Populations were propagated with selection for either planktonic growth
through a daily 1:100 dilution or bioﬁlm growth through a daily bead transfer, which forces cells to
undergo the entire bioﬁlm life cycle of attachment, growth, dispersion, and reattachment every 24 h, as
described in previous work (79). (C) Tobramycin resistance level relative to that for the ancestral clone
for three randomly chosen populations per treatment after 12 days of evolution. MICs were determined
by microdilution in Mueller-Hinton broth according to CLSI guidelines. The fold change in the MIC for
three replicates per population is shown, with the median fold change and range indicated. The A.
baumannii ancestral clone MIC was 1.0 mg/liter and the P. aeruginosa ancestral clone MIC was 0.5 mg/
liter in Mueller-Hinton broth. Populations had to acquire resistance to TOB at a concentration 4⫻ the MIC
for the ancestral strain in order to survive the experiment (gray dashed line).

®
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FIG 2 Population sequencing reveals interspecies parallelism and the lifestyle-associated molecular
targets of evolution. Mutations identiﬁed by whole-population genome sequencing of tobramycintreated populations of A. baumannii and P. aeruginosa. Five populations per treatment were sequenced
after 12 days of experimental evolution. Shading indicates the total frequency of all mutations in each
gene within a population at day 12.

To distinguish the speciﬁc contributions of mutations in these genes to TOB
resistance, we obtained isogenic mutants by isolating clones from evolved A. baumannii and P. aeruginosa populations and genotyping them by WGS. We measured by broth
microdilution the TOB MICs for seven isogenic fusA1 mutants, including A. baumannii
mutants with the R59H and G460V mutations and P. aeruginosa mutants with the
Q129H, N592I, F596L, Q678L, and R680C mutations (Table 1). Regardless of the species
or amino acid change, fusA1 mutations conferred an increase in TOB resistance con-

MIC (mg/liter)
Species
Genotype
A. baumannii Ancestor
fusA1 R59H
fusA1 G460V
cyoA V53V ptsP indel of nt 1742/2295
ACX60_RS12470 A173D
fusA1 G460V ptsP indel of nt 1340–1368/2295
fusA1 G460V ptsP indel of nt 1788/2295
fusA1 F535L ptsP Δ2bp 587–588/2295
ACX60_RS04175 R62C
P. aeruginosa Ancestor
fusA1 Q129H
fusA1 N592I
fusA1 F596L
fusA1 Q678L
fusA1 R680C
ptsP Δ42bp (deletion of nt 1846–1887/2280)
ptsP Δ14bp (deletion of nt 1296–1309/2280)
fusA1 Q678L ptsP R301C
fusA1 T456A ptsP V661E
fusA1 Q563L ptsP E335*
fusA1 R680C ptsP E335*
fusA1 T671A ptsP Δ1bp (deletion of nt 1122/2280)
fusA1 N592I orfN Δ1bp (deletion of nt 148/1017)
aData
bFold

Fold
changeb

Median
1.0
4.0
4.0
4.0

Range
1.0–2.0
2.0–4.0
4.0–8.0
2.0–4.0

8.0
8.0
8.0

8.0–8.0 8.0
8.0–8.0 8.0
8.0–16.0 8.0

0.5
1.5
2.0
2.0
2.0
1.0
1.0
1.5
4.0
2.0
4.0
4.0
4.0
2.0

0.25–1.0
1.0–2.0
2.0–2.0
1.0–2.0
1.0–2.0
1.0–2.0
1.0–2.0
1.0–2.0
1.0–4.0
1.0–4.0
2.0–4.0
2.0–4.0
2.0–8.0
2.0–4.0

4.0
4.0
4.0

3.0
4.0
4.0
4.0
2.0
2.0
3.0
8.0
4.0
8.0
8.0
8.0
4.0

are from 4 replicates.
change in the MIC from that for the ancestor.
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TABLE 1 Evolved mutant clones genotyped by WGS demonstrate increased TOB
resistance (MIC) relative to the ancestral clonea
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sisting of an increase in the MIC of 2 to 4 times the MIC for the ancestor. We also
measured the resistance levels of two ptsP mutants of P. aeruginosa (the Δ42bp mutant,
in which nucleotides [nt] 1846 to 1887/2295 were deleted, and the Δ14bp mutant, in
which nt 1296 to 1309/2295 were deleted) and found that these mutations produce
similar increases in resistance (MICs 2 and 3 times the MIC for the ancestor, respectively). Mutants of both species with both fusA1 and ptsP mutations generally exhibited
higher levels of resistance to TOB than mutants with the fusA1 or ptsP mutation alone
(4⫻ to 8⫻ the MIC for the ancestral clone) at a level that is consistent with an additive
effect of these two mutations on the MIC. To examine if these mutations produced
increased resistance in a bioﬁlm environment, we treated polystyrene beads colonized
with fusA1, ptsP, and fusA1 ptsP mutants with TOB. Bioﬁlms of the evolved mutants
survived in the presence of concentrations of TOB at least 3 times higher than the
concentration in the presence of which bioﬁlms composed of the ancestral genotype
survived (Table S1), suggesting that these mutations also increased TOB resistance in a
bioﬁlm environment. Mutations in fusA1 also increased the MICs of other ribosometargeting antibiotics, including amikacin, gentamicin, and tigecycline; however, mutations in ptsP did not produce cross-resistance to the other antibiotics tested (Fig. S3A),
suggesting speciﬁcity to TOB resistance. While species-speciﬁc mutations did occur in
several genes, as discussed below, the parallel evolution of mutations in fusA1 and ptsP
across A. baumannii and P. aeruginosa indicates that, regardless of genetic background,
mutations to these two genes are among the few that jointly increase TOB resistance
and ﬁtness under these conditions.
Environment-associated adaptations to TOB selection. Bacterial growth in different environments often involves distinct physiological processes, including nutrient
uptake, metabolic pathways, growth rates, and investment in defenses (41). Consequently, the stresses produced by a given antibiotic may vary in different environments.
Experimental evolution under both planktonic and bioﬁlm conditions allows us to test
if the genetic pathways of adaptation depend on the external environment. TOB
selection enriched multiple mutations in fusA1 within each population regardless of the
environment, but their frequencies differed with lifestyle. For P. aeruginosa, fusA1
mutations dominated bioﬁlm populations in the ﬁnal sample (mean ⫾ standard deviation, 95.4% ⫾ 3.7%), but their frequencies varied in planktonic populations
(mean ⫾ standard deviation, 50.4% ⫾ 25.7%) (Fig. 2). Furthermore, 12 distinct mutations in ptsP rose to detectable frequencies in P. aeruginosa lineages, and 11 of these
occurred in planktonic populations, demonstrating a strong selection for ptsP mutations under the planktonic growth condition that is less pronounced than that under
the bioﬁlm growth condition (Data Set S2). Meanwhile, P. aeruginosa bioﬁlm populations frequently acquired mutations in the orfK, orfH, orfL, or orfN gene (subsequently
referred to jointly as orfKHLN), encoding O antigen biosynthesis enzymes, and this locus
was mutated in only one of the planktonic populations exposed to TOB (42, 43). A
mutation in orfK also occurred at a low frequency in a population with no TOB selection,
suggesting that these mutations may be beneﬁcial under a variety of conditions but
most beneﬁcial in the combination of bioﬁlm growth and TOB selection (Fig. S2).
Indeed, mutants with orfN mutations together with fusA1 mutations were more resistant than mutants with the fusA1 mutation alone in the experimental medium (Fig. S3B)
and increased bioﬁlm production (Fig. S3C).
The genetic targets of resistance were more consistent in A. baumannii populations
treated with TOB, with the fusA1 and ptsP mutations reaching similar frequencies in
both the bioﬁlm and planktonic treatments by the end of the experiment. However, six
independent mutations in cyoA and cyoB (subsequently referred to jointly as cyoAB),
encoding components of the electron transport chain, rose to detectable frequencies
prior to day 12, and all of these occurred in the bioﬁlm lineages (Fig. 2; Fig. S4) (7).
Together, the parallel evolution of mutations in orfKHLN and cyoAB in the bioﬁlm
lineages but not the planktonic lineages indicates that lifestyle may inﬂuence the
strength of selection for certain TOB resistance mutations.
May/June 2020 Volume 11 Issue 3 e00932-20
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The parallel evolution of mutations in four genes associated with O antigen biosynthesis in P. aeruginosa suggests that selection favors alterations in the outer
membrane when bioﬁlm populations are exposed to TOB (8, 42, 44). Consistent with
this observation, mutations in orfN, a homolog of wbpL in strain PAO1, have been
shown to cause the loss of the O-speciﬁc antigen in the strain PA14 lipopolysaccharide
(LPS), a phenotype which frequently arises during chronic P. aeruginosa infection in
cystic ﬁbrosis (CF) patients (44). This loss of O-speciﬁc antigen also increases resistance
to aminoglycosides by reducing permeability and the binding afﬁnity to the outer
membrane (45, 46). Together, these reports indicate that the selected orfKHLN mutations may produce TOB resistance by altering the outer membrane to reduce drug
binding or uptake. Similarly, populations of A. baumannii evolved with TOB and bioﬁlm
selection acquired mutations in the cyoAB operon. Mutations in electron transport
chain components, like cyoAB, have previously been suggested to increase resistance to
aminoglycosides by reducing membrane permeability (33, 47, 48). Therefore, although
the bioﬁlm populations of the two species propagated in this experiment evolved
mutations in different loci (affecting LPS biosynthesis genes in P. aeruginosa and
electron transport chain components in A. baumannii), these may represent the parallelism of a broad strategy to alter the membrane structure or permeability under
combined bioﬁlm and aminoglycoside selection.
Population genetic dynamics of TOB resistance evolution. We used longitudinal
population sequencing of three lineages per treatment to determine the effects of
species and the environment on the temporal dynamics of evolution in the presence of
increasing concentrations of TOB. The frequencies of mutated alleles within a population were plotted over time to display mutation trajectories (Fig. S4). Next, to infer
genotypes based on allele frequency data, we developed and implemented a novel set
of computational tools which applies a hierarchical clustering algorithm to genetic
distance metrics. The lineage of genotypes was subsequently inferred using a Bayesian
approach. This application then illustrates the observed dynamics of genotypes over
the course of evolution through Muller plots (Fig. 3; see Materials and Methods).
Genotype frequency is represented by the breadth of shading with colors corresponding to the presence of the fusA1, ptsP, cyoAB, and orfKHLN mutations within that
genotype.
In all lineages, regardless of the environment, mutations in fusA1 were detected at
either 0.5⫻ MIC or 1.0⫻ MIC and subsequently rose to high frequencies (Fig. 3, red).
Their rapid rise in frequency in the ﬁrst few days of the experiment suggests that fusA1
mutations were the ﬁttest contending mutations at subinhibitory concentrations of
TOB. Some fusA1 mutations, for example, fusA1 G460V, occurred in multiple independent lineages. Given the extensive gene-level parallelism observed in these experiments, these mutations may reﬂect parallel evolution at the amino acid level, but we
cannot exclude the possibility that these mutations were introduced at undetectable
frequencies in the starting culture (Fig. S4). However, 20 distinct mutations in fusA1
were selected in lineages treated with TOB and never detected in drug-free lineages,
demonstrating that fusA1 mutations were acquired and highly advantageous under
TOB selection. Lineages with different fusA1 single nucleotide polymorphisms (SNPs)
coexisted in some populations for the duration of the experiment, and secondary
mutations were frequently selected on these genotypes in the genes discussed above
(ptsP, orfKHLN, and cyoAB; Fig. 3). A. baumannii populations tended to become dominated by fusA1 ptsP genotypes, but all three bioﬁlm populations also selected cyoAB
mutants prior to day 9 (up to 2⫻ MIC). This cyoAB genotype was ultimately outcompeted by a fusA1 ptsP genotype at 4⫻ MIC of TOB, indicating the superiority of the latter
genotype at the higher drug concentration. This result was conﬁrmed by comparisons
of the MICs for the cyoA ptsP and fusA1 ptsP mutants, which showed that mutants with
the former genotype were unable to survive in the presence of the ﬁnal antibiotic
concentration in the evolution experiment (Table 1). In planktonic populations of P.
aeruginosa, the fusA1, ptsP, and fusA1 ptsP haplotypes were prevalent throughout the
May/June 2020 Volume 11 Issue 3 e00932-20
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FIG 3 Evolutionary dynamics of bacterial populations in increasing concentrations of tobramycin. Muller plot diagrams display the
genotype frequencies as a proportion of the population throughout 12 days of evolution for three populations per treatment. Genotypes
are shaded by the putative driver loci that are mutated. Different lineages of the same color represent mutations at different positions within
the same locus that coexist within the population. The frequency of genotypes at every time point is represented by the height of the graph
that it spans at that time point. In situations in which a ﬁrst mutation arises in the background of the ancestral genotype, the color
representing that genotype can be seen beginning from the white background, whereas in situations in which a mutation arises in the
background of another mutation, thus generating a new genotype, the new color arises in the middle of the existing genotype. Mutations
occurring in the background of putative driver mutations are not shown but may be viewed in linear allele frequency plots of each
population in Fig. S4 in the supplemental material.
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experiment (Fig. 3). In contrast, bioﬁlm populations of P. aeruginosa repeatedly selected
orfKHLN mutants on a fusA1 background. These evolutionary dynamics demonstrate
that, following the initial selection of a fusA1 mutation, selection favored secondary
mutations particular to the lifestyle and the species.
Parallelism of aminoglycoside resistance mechanisms across species. The repeated evolution of the fusA1 and ptsP mutations in both P. aeruginosa and A.
baumannii suggested that these mutations may provide a general mechanism of TOB
resistance across diverse species. We tested this hypothesis by searching published
data sets and genomes for fusA1, ptsP, cyoA, and cyoB mutations (see Materials and
Methods). Mutations in fusA1 have been reported in several different species, including
Escherichia coli, Salmonella enterica, and Staphylococcus aureus (7, 38, 49–52), and all
laboratory studies reported that these mutations either arise in response to aminoglycoside selection or are a direct cause of aminoglycoside resistance (Fig. 4A).
Mutations in cyoA and cyoB were also found in E. coli and S. enterica in these
experiments (7, 26, 49).
We performed multiple-sequence alignments of the proteins encoded by fusA1
(EF-G), ptsP, cyoA, and cyoB for all of the species that acquired mutations within each
locus (Table S2). We subsequently plotted all of the identiﬁed aminoglycosideassociated mutations according to their position in the consensus sequence to examine
the distribution of mutations within the proteins (Fig. 4; Fig. S5). Most mutations
selected in ptsP were indels producing a frameshift, demonstrating that the ﬁtness
advantage conferred by these variants results from a loss of function of the product
(Fig. 4). Mutations affecting cytochrome components encoded by cyoAB acquired
frameshift, stop codon, nonsynonymous, and synonymous variants, including an unusual mutation changing the start codon from AUG to AUU (Data Set S2). In contrast,
mutations in EF-G occurred at 57 distinct amino acid positions and were nearly
exclusively nonsynonymous SNPs. Because fusA1 is an essential gene (53, 54) that is
highly conserved (44% amino acid identity across the ﬁve species studied and much
greater similarity), these mutations must presumably both increase ﬁtness in the
presence of an aminoglycoside and maintain the essential functions of the protein.
The distribution of mutations within EF-G was similar across species and clustered
primarily between amino acids 21 and 184 or between amino acids 327 and 695 in all
species tested, with the exception of E. coli, in which mutations occurred only near the
C terminus (Fig. 4; Fig. S5) (55). To test the likelihood that this clustering of mutations
within EF-G could occur by chance, we divided EF-G into different bins and then used
a chi-square goodness-of-ﬁt test to determine if the observed count of mutations
within bins differed from expectation based on bin size. The test was signiﬁcant using
three different binning strategies: binning mutations by protein domain (chi-square
test value ⫽ 36.956, degrees of freedom [df] ⫽ 4, P ⫽ 1.839e⫺07), by 100-amino-acid
intervals (chi-square test value ⫽ 54.175, df ⫽ 7, P ⫽ 2.172e⫺09), and by ﬁve randomly
determined bins (chi-square test value ⫽ 41.957, df ⫽ 4, P ⫽1.703e⫺08). Further, 10
amino acids of the EF-G consensus sequence repeatedly evolved mutations (at amino
acids 122, 461, 472, 592, 596, 663, 671, 672, 680, and 681), revealing strong selection on
particular sites of EF-G in response to aminoglycoside treatment regardless of the
genetic background or growth conditions. We visualized mutated positions on the
crystal structure of P. aeruginosa EF-G (Fig. 4B) (56) and identiﬁed further spatial
clustering of the mutated residues. The mutations affected domains I (GTPase), III, IV,
and V frequently, but occurred only once in domain II in these studies, which suggests
that mutations to this region either are deleterious to the function of EF-G, do not
confer an increase in resistance to aminoglycosides, or fulﬁll these criteria but produce
variants less advantageous than those that rose to high frequencies in these experiments.
When antibiotic resistance occurs through mutations in essential gene products,
one might expect that selection would favor peptide alterations that prevent drug
action but that retain the core functionality of the enzyme or structure. More speciﬁMay/June 2020 Volume 11 Issue 3 e00932-20
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FIG 4 Parallelism of mutations in genetic loci associated with aminoglycoside resistance across species. (A) All mutations
that occurred at any point in the experiment within the fusA1, ptsP, cyoA, or cyoB gene are indicated by a symbol at their
position within the consensus amino acid sequence. Mutations reported in previous literature in other species are
indicated and color coded by species; these mutations were either selected by aminoglycoside treatment in vitro or
selected by another antibiotic and subsequently demonstrated to confer resistance to aminoglycosides. SNPs are indicated
by circles, insertions or deletions (indels) are indicated by triangles, and stop codon mutations are indicated by asterisks.
For each gene, the encoded amino acid sequences for all species in which mutations were identiﬁed were aligned.
Mutations are shown according to their position in the resulting consensus amino acid sequence. (Top) fusA1 gene;
(middle) ptsP gene; (bottom) cyoA and cyoB genes. The referenced literature is identiﬁed as follows: 1, Johanson and
Hughes (38); 2, Jahn et al. (49); 3, Ibacache-Quiroga et al. (7); 4, Mogre et al. (51); 5, Kim et al. (50); 6, Norström et al. (52);
7, Wistrand-Yuen et al. (26). (B) Amino acid positions that were mutated in any species are shown in blue on the protein
structure of the strain PAO1 EF-G (56). Mutations are shown according to their corresponding position in the P. aeruginosa
EF-G amino acid sequence. Domains G (GTPase), II, III, IV, and V are indicated.

cally, selection might select for mutations that alter residues that are more tolerant of
variation and that vary among extant homologs rather than strictly conserved residues.
We tested whether mutations in EF-G occurred less frequently in amino acid positions
that were identical across species. On the contrary, SNPs occurred at positions with
identical amino acids across species more frequently than expected by chance for EF-G
(Fig. S5) (P ⫽ 8.002e⫺05, Fisher’s exact test). The mechanism by which these mutations
produce aminoglycoside resistance without disrupting the essential functions of EF-G
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mbio.asm.org 10

Downloaded from https://journals.asm.org/journal/mbio on 23 July 2021 by 134.48.159.153.

Scribner et al.

®

Parallel Evolution of Antibiotic Resistance

TABLE 2 Data sets of P. aeruginosa clinical isolates were analyzed to reveal gene and
residue-level parallelism within the aminoglycoside resistance loci observed in this study
Variants
Study authors (reference)
López-Causapé et al. (58)
Markussen et al. (60)
Chung et al. (57)
Bolard et al. (24)
aMutations

fusA1
V93A, K430E, N482S, K504E, Y552C,
P554L, D588G, P618L, T671Ia
G118S, D467G
A418T, V538A, G610V, Q678Ra
V93A, A555E, T671Aa

ptsP

L42L, R61H

at this amino acid position occurred in populations treated with TOB in this study.

DISCUSSION
The rapidly intensifying problem of antimicrobial resistance demands an understanding of how antibiotic resistance evolves and which types of mutations or mobile
elements are common causes (61, 62). Genetic screens of mutant collections have
revealed potential resistance mechanisms (33), and more recently, evolve-andresequence experiments have been used to identify the resistance mutations that
produce the greatest ﬁtness advantages under a given condition (8, 16, 37). However,
the broader clinical utility of these screens for predicting the evolution of antibiotic
resistance depends upon the relevance of the ﬁndings in other strains, species, or
environments. This study served the dual purpose of identifying mutations that contribute to TOB resistance in A. baumannii and P. aeruginosa and demonstrating the
effects of different environments and species histories on the evolutionary dynamics
and causes of resistance.
In spite of the many genetic differences between A. baumannii and P. aeruginosa
(the genome of the latter is much larger and contains dozens of additional putative
resistance loci), we identiﬁed parallel mutations in fusA1 and ptsP following tobramycin
selection, a largely unknown combination of mutations conferring high levels of ﬁtness
and resistance. Furthermore, we found amino acid-level parallelism of fusA1 mutations
associated with aminoglycoside resistance, including kanamycin, gentamicin, and amikacin resistance, across diverse species, including E. coli, S. enterica, and S. aureus (Fig. 4;
see also Fig. S5 in the supplemental material). While speciﬁc molecular targets of
resistance shared by multiple species, for example, DNA gyrase mutations in response
to ﬂuoroquinolones, are known (8), the level of predictability of fusA1 mutations has yet
to be appreciated as an example of this phenomenon. We report that fusA1 mutations
not only arise during aminoglycoside treatment in at least ﬁve diverse species but also
produce resistance to nearly every antibiotic within this clinically useful family of drugs
(25). Furthermore, the level of parallelism detected distinguishes this study from merely
episodic discoveries of fusA1 mutations in multiple species. On the contrary, we found
at least one fusA1 mutation in every TOB-treated lineage in our study, making these
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merits further study. Regardless, the parallel evolution of fusA1 mutations across
species and environments demonstrates the potential utility of this gene as a predictive
marker of aminoglycoside resistance.
To examine if the precise mutations found in our in vitro study also arise in clinical
isolates, we searched published genomes of P. aeruginosa clinical isolates from patients
who had likely been treated with aminoglycosides, like TOB (24, 57–60). Mutations
within fusA1 and ptsP were reported in these genomes, suggesting that these mutations evolve during infections (Table 2). Although it was not possible to distinguish
aminoglycoside selection as the driver of these mutations in a clinical setting, the
selection of mutations at identical residues in our evolution experiment suggests that
these mutations have the potential to produce the same increase in aminoglycoside
resistance in vivo. Taken together, the parallel evolution of mutations in these genes in
clinical isolates suggests that they may contribute to aminoglycoside resistance in
clinically relevant genetic backgrounds and environments, including infections of the
cystic ﬁbrosis respiratory tract.

®

mutations both widely available and highly predictable. The locations of mutations
within EF-G revealed that the distribution of mutations was also similar across species
(Fig. 4), but unlike other resistance targets that frequently acquire mutations in speciﬁc
sites or narrow regions (10, 63, 64), the EF-G mutations were distributed across
the length of the protein (Fig. 4). Alterations in EF-G have been suggested to produce
structural changes that could interfere with aminoglycoside binding to the ribosome
(24), but the mechanism(s) by which mutations across much of the protein all produce
aminoglycoside resistance and how they alter protein function merit further study. The
ﬁnding that fusA1 mutations repeatedly evolve in clinical P. aeruginosa isolates from
different strains and under different host conditions further supports the notion that
these mutations are selected in diverse genetic backgrounds and environments, and
we predict that, following antibiotic therapy, fusA1 mutations may be considerably
more prevalent than was previously appreciated. Mutations in fusA1 also produced
cross-resistance to other ribosome-targeting antibiotics in P. aeruginosa, a concerning
ﬁnding, given the frequent use of tobramycin in treating infections of the CF airway
(Fig. S3) (65).
Bacterial growth in bioﬁlms also demonstrably altered the targets of TOB selection
from those in well-mixed cultures in ways that motivate studies of the predominant
mechanism of aminoglycoside killing and resistance when bacteria grow on surfaces or
in aggregates. The selection of mutations in LPS biosynthesis genes (orfKHLN) and
electron transport chain components (cyoAB) primarily in bioﬁlm populations indicates
that resistance may have resulted from altered TOB binding or uptake in this lifestyle.
In addition to tobramycin’s mode of killing by disrupting translation, it has also been
shown to exhibit a second, translation-independent killing mechanism by binding to
the membrane (22, 46). Furthermore, aminoglycosides have been shown to induce cell
killing in various types of nonreplicating bacteria (66). The enrichment of resistance
mechanisms that alter drug binding or uptake in bioﬁlm lineages may imply that the
slow-growing, sessile cells in a bioﬁlm experience weaker selection for mutations
preserving translation but an increased demand to prevent tobramycin binding and
uptake. More generally, these lifestyle distinctions in resistance traits suggest that the
environment may inﬂuence the evolutionary dynamics of antimicrobial resistance, in
concordance with the ﬁndings of previous studies (2, 16, 31). Therefore, while mutations in genes like fusA1 represent mechanisms of resistance that are robust across a
wide range of species, environments, and host conditions, considering the prevailing
mode of bacterial growth may also improve predictions of other genetic causes of
antimicrobial resistance.
The extent of parallelism in molecular evolution in these experiments is surprising,
and its causes warrant consideration. Why would widely different species evolve to
resist tobramycin by fusA1 mutations and, to a lesser extent, ptsP mutations when many
causes of aminoglycoside resistance are likely available (33)? Several possible explanations that are not mutually exclusive exist. One possibility is that these genes possess
a high local mutation rate and thus acquire mutations more rapidly than other available
molecular targets of resistance. However, it is doubtful that these mutations are more
available than others, since neither was enriched in studies of mutations accumulated
in the near absence of selection, nor are these mutations in loci in genome regions
shown to have higher mutation rates (67, 68). Another possibility is that the target sizes
of fusA1 and ptsP (and, to a lesser extent, orfKHLN and cyoAB), in which multiple
nonsynonymous mutations produce resistance, increase the likelihood of gene-level
parallelism. More likely still is the possibility that mutations in fusA1 and ptsP produce
the greatest ﬁtness beneﬁt under these conditions and that these ﬁtness beneﬁts are
robust to different species and environments. Other drugs may have a wider range of
targets that produce the same level of ﬁtness beneﬁt, resulting in less parallelism.
It is notable that while fusA1 and ptsP are not direct targets of TOB or other
aminoglycosides, the effect of mutations in these enzymes may be conserved across
species and is relatively insensitive to the genetic background. Many have appreciated
that epistatic interactions can limit the parallel evolution of resistance mechanisms
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(69–72) and, hence, predictability (73, 74). The gene- and nucleotide-level parallelism of
molecular targets of aminoglycoside resistance across species, environments, and
clinical isolates holds promise for predicting molecular evolution, improving diagnostics for resistance, and informing more rational treatment design.

Strains and media. Pseudomonas aeruginosa strain UCBPP-PA14 and Acinetobacter baumannii strain
ATCC 17978 were the ancestral strains used in the evolution experiments (75–77). A. baumannii ATCC
17978 was propagated for 10 days in minimal medium to preadapt it to the medium conditions prior to
the evolution experiment. The minimal medium used in the evolution experiments consisted of an M9
salt base (0.1 mM CaCl2, 1.0 mM MgSO4, 42.2 mM Na2HPO4, 22 mM KH2PO4, 21.7 mM NaCl, 18.7 mM
NH4Cl), 11.1 mM glucose, 20-ml/liter minimal essential medium (MEM) essential amino acid solution and
10-ml/liter MEM nonessential amino acid solution (catalog numbers 11130051 and 11140050; Thermo
Fisher), and 1 ml/liter each of trace elements A, B, and C (catalog numbers 99182CL, 99175CL, and
99176CL; Corning). In addition, DL-lactate (catalog number 72-17-3; Sigma-Aldrich) was added to the P.
aeruginosa medium to a ﬁnal concentration of 10 mM in order to generate the approximate nutrient
concentrations present in the cystic ﬁbrosis lung environment (78). All cultures were grown in 18- by
150-mm glass tubes containing 5 ml of minimal medium and incubated at 37°C in a roller drum (30 rpm).
Evolution experiment. Evolution experiments in both P. aeruginosa and A. baumannii were initiated
using a single ancestral clone. For P. aeruginosa, a single colony was selected, resuspended in phosphatebuffered saline (PBS), and then used to inoculate 20 replicate lineages. For A. baumannii, a single colony
was selected, grown in minimal medium with no antibiotic for 24 h, and then used to inoculate 20
replicate lineages. The lineages were propagated with either increasing concentrations of TOB or no TOB
and either planktonic or bioﬁlm selection, such that ﬁve replicate lineages each were propagated for four
experimental conditions (planktonic growth without TOB, planktonic growth with TOB, bioﬁlm growth
without TOB, and bioﬁlm growth with TOB) for each organism. Lineages with planktonic selection were
propagated through a 1:100 dilution every 24 h (50 l in 5 ml of fresh minimal medium), and lineages
with bioﬁlm selection were propagated by transferring a colonized polystyrene bead (Cospheric, Santa
Barbara, CA) to a tube of fresh medium and three fresh beads every 24 h, as described previously (78, 79).
P. aeruginosa bioﬁlm transfers were performed by transferring a bead directly to the next day’s tube,
whereas A. baumannii bioﬁlm transfers were performed by ﬁrst rinsing the bead by transferring it to a
tube of PBS and then transferring the bead to the next day’s tube. Lineages propagated with antibiotic
selection were treated with tobramycin sulfate (Alfa Aesar, Wardhill, MA) starting at 0.5⫻ MIC for the
ancestral strain in the experimental minimal medium (0.5 mg/liter for A. baumannii and 2.0 mg/liter for
P. aeruginosa), with doubling of the concentration every 72 h. The experiment was performed for 12 days,
with samples collected on days 3, 4, 6, 7, 9, 10, and 12 and frozen at ⫺80°C in either 25% glycerol for
P. aeruginosa or 9% dimethyl sulfoxide for A. baumannii. Planktonic lineages were sampled by freezing
an aliquot of the liquid culture, and bioﬁlm lineages were sampled by sonicating a bead in PBS and
freezing an aliquot of the resuspended cells.
MIC assays. We determined MICs by broth microdilution in Mueller-Hinton broth according to
Clinical and Laboratory Standards Institute guidelines (32). To measure the MICs for evolved populations,
we revived frozen populations by streaking of the populations onto a tryptic soy agar plate, resuspended
a portion of the resulting bacterial lawn in PBS, and diluted the suspension to a 0.5 McFarland standard.
We inoculated the suspension into round-bottom 96-well plates containing 2-fold dilutions of TOB at a
ﬁnal concentration of 5 ⫻ 105 CFU/ml. The P. aeruginosa and A. baumannii MIC assay mixtures were then
incubated at 37°C for 16 to 20 h or 18 to 22 h, respectively, and then the MIC was determined as the
concentration in the ﬁrst well that showed no growth. At least three assays were performed for each
population. In P. aeruginosa, the MICs of TOB differed between when they were measured in MuellerHinton broth and when they were measured in the experimental minimal medium, but they reﬂected
similar fold changes in the MIC relative to the MIC for the ancestral clone (see Fig. S1 in the supplemental
material). The MICs for the clones were measured by the same procedure, with the exception that freezer
stocks were streaked for isolation and MIC assays were performed using an isolated colony. The MICs of
other ribosome-targeting antibiotics for the fusA1 and ptsP isogenic mutants were determined using
Sensititre plates according to the manufacturer’s speciﬁcations (Sensititre GN3F; Trek Diagnostics Inc.,
Westlake, OH).
Although mutations to orfKHLN were frequent in the tobramycin-treated populations, only a small
increase in the MIC was observed by the microdilution method in Mueller-Hinton broth. We therefore
measured the MICs of isogenic fusA1 and fusA1 orfN mutants by macrodilution in minimal medium to
better represent the conditions of the evolution experiment. Twofold dilutions of TOB in 5 ml of minimal
medium were inoculated with 5 ⫻ 105 CFU/ml for each genotype, the cultures were incubated for 18 h,
and the MIC was determined from the well with the lowest concentration with no visible growth.
The TOB MIC for the evolved clones in a bioﬁlm environment was measured by inoculating tubes
containing 5 ml of Mueller-Hinton broth and 5 polystyrene beads with each isogenic mutant and
incubating for 24 h. Each colonized bead was then transferred to a fresh tube of Mueller-Hinton broth
at 2-fold dilutions of TOB and treated for 18 h. The beads were transferred to 1 ml PBS and sonicated, and
then 10 l was transferred to 100 l of fresh medium and incubated for 24 h. The MIC was reported as
the lowest concentration of TOB at which no growth occurred (optical density at 600 nm [OD600] ⬍ 0.05)
after this 24-h incubation. This MIC reﬂects the lowest TOB concentration that produced effective killing
of the bioﬁlm. MIC is reported as the median value from at least three replicates in all MIC experiments.
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Bioﬁlm assays. The bioﬁlm production of mutants isolated from evolved populations was determined by a crystal violet assay using a previously described protocol (80). Overnight cultures of the
mutants in the experimental minimal medium were diluted 1:100 in fresh minimal medium to a volume
of 200 l in a 96-well dish. The plates were incubated for 24 h at 37°C and then rinsed twice with water.
The wells were stained with 250 l of 0.1% crystal violet, and the plates incubated for 15 min, rinsed
three times with water, and then allowed to dry overnight. Crystal violet was solubilized by adding 250 l
95% ethanol (EtOH) solution (95% EtOH, 4.95% distilled H2O, 0.05% Triton X-100) to each well for 15 min.
Bioﬁlm formation was then visualized by measuring the OD600. The results are the averages from four
replicates.
Genome sequencing and analysis. Whole populations were sequenced periodically throughout the
experiment. For TOB-treated lineages, all populations were sequenced on day 12, and 3 lineages from
each of the planktonic and bioﬁlm conditions were also sequenced on days 3, 4, 6, 7, 8, 9, and 10 for P.
aeruginosa and days 1, 3, 4, 6, 7, 9, and 10 for A. baumannii. Three no-TOB lineages from each of the
bioﬁlm and planktonic conditions were also sequenced on days 6 and 12 for P. aeruginosa and days 1,
4, 9, and 12 for A. baumannii.
Populations were prepared for sequencing by inoculating freezer stocks of the bacterial populations
into the same medium and the same antibiotic concentration in which the population was growing at
the time of freezing. Growth conditions identical to the population’s growth conditions at the time of
freezing were maintained in order to minimize bias in the population structure during the outgrowth
process. After 24 h of growth, populations were sampled by either removing an aliquot of the culture for
planktonic populations or transferring beads to PBS, sonicating, and removing an aliquot of the
resuspended cells for bioﬁlm populations. DNA was extracted using a DNeasy blood and tissue kit
(Qiagen, Hilden, Germany). The sequencing library was prepared as described by Turner and colleagues
(30), according to a previously described protocol (81) using an Illumina Nextera kit (Illumina Inc., San
Diego, CA), and sequenced using an Illumina NextSeq500 sequencer. Samples were sequenced to 160⫻
coverage, on average, for P. aeruginosa populations and 309⫻ coverage, on average, for A. baumannii
populations.
Sequences were trimmed using Trimmomatic (v0.36) with the following criteria: leading, 20; trailing,
20; slidingwindow, 4:20; minlen,70 (82). Breseq (v0.31.0) was used to call variants using the default
parameters and the -p ﬂag when analyzing population sequences (83). These parameters call mutations
only if they are present within the population at a frequency of at least 5% and are in at least 2 reads
from each strand. The A. baumannii ATCC 17978-mff genome (GenBank accession number NZ_CP012004)
and plasmid (GenBank accession number NZ_CP012005) sequences were downloaded from the RefSeq
database. Two additional plasmids (GenBank accession numbers CP000522 and CP000523) were found
to exist in our working strain and were added to this reference genome. The P. aeruginosa UCBPP-PA14
genome was downloaded from the RefSeq database (GenBank accession number NC_008463). Mutations
were removed if they were also found in the ancestor’s sequence when mapped to the reference
genome. Mutations that did not reach a cumulative frequency of at least 25% across all populations at
all time points were removed, and mutations were also manually curated to remove biologically
implausible mutations. A mutation was determined to be biologically implausible if it occurred either (i)
at trajectories that were not possible given the trajectories of the putative driver mutations or (ii) only
at the ends of reads, only in reads with many other mutations, or only at a low coverage (⬍10 reads),
indicating poor read mapping at that region. When high-quality mutations in loci related to the putative
driver loci or ribosome machinery were reported in New Junction Evidence by breseq, these mutations
were also included in the analysis. Mutations ﬁtting these criteria included mutations to 23S rRNA in P.
aeruginosa and mutations to ptsP, phosphocarrier protein HPr, and NADH quinone oxidoreductase in A.
baumannii. Filtering, allele frequencies, and plotting were done in R software (v3.5.3; www.r-project.org)
with the packages ggplot2 (v2.2.1; https://CRAN.R-project.org/package⫽ggplot2) and tidyr (https://CRAN
.R-project.org/package⫽tidyr). Muller plots were generated by C.D. using the lolipop package (v0.5.2;
https://github.com/cdeitrick/lolipop) and the default parameters. These scripts predict genotypes and
lineages based on the trajectories of mutations over time using a hierarchical clustering method and
implement ﬁltering criteria to eliminate singletons that do not comprise prevalent genotypes. Muller
plots were manually color coded by the presence of putative driver mutations within each genotype.
Additional mutations that occurred on the background of putative driver mutations can be viewed in the
allele frequency plots but are not shown in Muller plots (Fig. 3; Fig. S4).
Resistance locus alignment and mutation mapping. Mutations in putative resistance loci (fusA1,
ptsP, cyoA, and cyoB) were identiﬁed in previous literature reporting that these mutations arose in
response to aminoglycoside selection or directly conferred an increase in aminoglycoside resistance by
an MIC assay. The amino acid sequences of the encoded proteins for these species were obtained by
searching the Features section of PATRIC for these genes in the genomes speciﬁed in these experiments
(55). The amino acid sequences were aligned in PATRIC, and the mutations reported in each study were
visualized according to the corresponding position in the sequence alignment (Fig. 4). We tested
whether the SNPs identiﬁed in each of these genes occur in conserved positions more frequently than
expected, considering the frequency of conserved positions within the genes, using a Fisher exact test
(Fig. S5). The protein structure of EF-G of P. aeruginosa strain PAO1 (PDB accession number 4FN5) was
obtained from the Protein Data Bank (PDB) (56, 84). All mutations associated with aminoglycoside
resistance were colored blue, according to the relative position of the mutation in the P. aeruginosa EF-G
protein sequence, using UCSF Chimera software (Fig. 4B) (85). Mutations in these genes in clinical isolates
were found by searching for whole-genome sequencing studies of P. aeruginosa isolates from cystic
ﬁbrosis patients that reported these mutations. Studies that identiﬁed fusA1 mutations in clinical isolates
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and reported increased aminoglycoside resistance in vitro for mutants with identical SNP changes were
also included (24).
Data availability. All sequencing reads were deposited in NCBI under BioProject accession numbers
PRJNA595915 and PRJNA485123. Detailed methods regarding data processing can be found at https://
github.com/michellescribner/tobramycin_analysis_code.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, PDF ﬁle, 0.04 MB.
FIG S2, PDF ﬁle, 0.1 MB.
FIG S3, PDF ﬁle, 0.1 MB.
FIG S4, PDF ﬁle, 0.1 MB.
FIG S5, PDF ﬁle, 0.2 MB.
TABLE S1, DOCX ﬁle, 0.01 MB.
TABLE S2, DOCX ﬁle, 0.02 MB.
DATA SET S1, XLSX ﬁle, 0.02 MB.
DATA SET S2, XLSX ﬁle, 0.02 MB.
ACKNOWLEDGMENTS
We thank Daniel Snyder and the Microbial Genome Sequencing center (MiGS) for
technical support.
This work was supported by the National Institute of Allergy and Infectious Diseases
at the National Institutes of Health (grant U01AI124302 and grant T32AI049820) and by
the Cystic Fibrosis Foundation Research Development Program.

1. Lässig M, Mustonen V, Walczak AM. 2017. Predicting evolution. Nat Ecol
Evol 1:e0077. https://doi.org/10.1038/s41559-017-0077.
2. Ahmed MN, Porse A, Sommer MOA, Høiby N, Ciofu O. 2018. Evolution of
antibiotic resistance in bioﬁlm and planktonic Pseudomonas aeruginosa
populations exposed to subinhibitory levels of ciproﬂoxacin. Antimicrob
Agents Chemother 62:e00320-18. https://doi.org/10.1128/AAC.00320-18.
3. Cooper VS. 2018. Experimental evolution as a high-throughput screen
for genetic adaptations. mSphere 3:e00121-18. https://doi.org/10.1128/
mSphere.00121-18.
4. Feng Y, Jonker MJ, Moustakas I, Brul S, ter Kuile BH. 2016. Dynamics of
mutations during development of resistance by Pseudomonas aeruginosa against ﬁve antibiotics. Antimicrob Agents Chemother 60:
4229 – 4236. https://doi.org/10.1128/AAC.00434-16.
5. Palmer AC, Kishony R. 2013. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat Rev Genet
14:243–248. https://doi.org/10.1038/nrg3351.
6. Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL.
2019. A large-scale whole-genome comparison shows that experimental
evolution in response to antibiotics predicts changes in naturally
evolved clinical Pseudomonas aeruginosa. Antimicrob Agents Chemother 63:e01619-19. https://doi.org/10.1128/AAC.01619-19.
7. Ibacache-Quiroga C, Oliveros JC, Couce A, Blázquez J. 2018. Parallel
evolution of high-level aminoglycoside resistance in Escherichia coli
under low and high mutation supply rates. Front Microbiol 9:427.
https://doi.org/10.3389/fmicb.2018.00427.
8. Wong A, Rodrigue N, Kassen R. 2012. Genomics of adaptation during
experimental evolution of the opportunistic pathogen Pseudomonas
aeruginosa. PLoS Genet 8:e1002928. https://doi.org/10.1371/journal.pgen
.1002928.
9. Fàbrega A, Madurga S, Giralt E, Vila J. 2009. Mechanism of action of and
resistance to quinolones. Microb Biotechnol 2:40 – 61. https://doi.org/10
.1111/j.1751-7915.2008.00063.x.
10. Wong A, Kassen R. 2011. Parallel evolution and local differentiation in
quinolone resistance in Pseudomonas aeruginosa. Microbiology 157:
937–944. https://doi.org/10.1099/mic.0.046870-0.
11. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, Earle S,
Pankhurst LJ, Anson L, de Cesare M, Piazza P, Votintseva AA, Golubchik
T, Wilson DJ, Wyllie DH, Diel R, Niemann S, Feuerriegel S, Kohl TA, Ismail
N, Omar SV, Smith EG, Buck D, McVean G, Walker AS, Peto TEA, Crook
DW, Iqbal Z. 2015. Rapid antibiotic-resistance predictions from genome
May/June 2020 Volume 11 Issue 3 e00932-20

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun 6:10063. https://doi.org/10.1038/ncomms10063.
Tamma PD, Fan Y, Bergman Y, Pertea G, Kazmi AQ, Lewis S, Carroll KC,
Schatz MC, Timp W, Simner PJ. 2018. Applying rapid whole-genome
sequencing to predict phenotypic antimicrobial susceptibility testing
results among carbapenem-resistant Klebsiella pneumoniae clinical isolates. Antimicrob Agents Chemother 63:e01923-18. https://doi.org/10
.1128/AAC.01923-18.
Gifford DR, Furió V, Papkou A, Vogwill T, Oliver A, MacLean RC. 2018.
Identifying and exploiting genes that potentiate the evolution of antibiotic resistance. Nat Ecol Evol 2:1033–1039. https://doi.org/10.1038/
s41559-018-0547-x.
Vogwill T, Kojadinovic M, Furió V, MacLean RC. 2014. Testing the role of
genetic background in parallel evolution using the comparative experimental evolution of antibiotic resistance. Mol Biol Evol 31:3314 –3323.
https://doi.org/10.1093/molbev/msu262.
Vogwill T, Kojadinovic M, MacLean RC. 2016. Epistasis between antibiotic
resistance mutations and genetic background shape the ﬁtness effect of
resistance across species of Pseudomonas. Proc Biol Sci 283:20160151.
https://doi.org/10.1098/rspb.2016.0151.
Santos-Lopez A, Marshall CW, Scribner MR, Snyder DJ, Cooper VS. 2019.
Evolutionary pathways to antibiotic resistance are dependent upon
environmental structure and bacterial lifestyle. Elife 8:e47612. https://
doi.org/10.7554/eLife.47612.
Santajit S, Indrawattana N. 2016. Mechanisms of antimicrobial resistance
in ESKAPE pathogens. Biomed Res Int 2016:2475067. https://doi.org/10
.1155/2016/2475067.
Eze EC, Chenia HY, Zowalaty M. 2018. Acinetobacter baumannii bioﬁlms:
effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect
Drug Resist 11:2277–2299. https://doi.org/10.2147/IDR.S169894.
Mulcahy LR, Isabella VM, Lewis K. 2014. Pseudomonas aeruginosa bioﬁlms in disease. Microb Ecol 68:1–12. https://doi.org/10.1007/s00248
-013-0297-x.
Hall CW, Mah T-F. 2017. Molecular mechanisms of bioﬁlm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev
41:276 –301. https://doi.org/10.1093/femsre/fux010.
Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic
resistance of bacterial bioﬁlms. Int J Antimicrob Agents 35:322–332.
https://doi.org/10.1016/j.ijantimicag.2009.12.011.
mbio.asm.org 15

Downloaded from https://journals.asm.org/journal/mbio on 23 July 2021 by 134.48.159.153.

REFERENCES

22. Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R,
Oliver A, Martin L, Shin BS, Forrest A, Tsuji BT. 2015. Two mechanisms of
killing of Pseudomonas aeruginosa by tobramycin assessed at multiple
inocula via mechanism-based modeling. Antimicrob Agents Chemother
59:2315–2327. https://doi.org/10.1128/AAC.04099-14.
23. Kohanski MA, Dwyer DJ, Collins JJ. 2010. How antibiotics kill bacteria:
from targets to networks. Nat Rev Microbiol 8:423– 435. https://doi.org/
10.1038/nrmicro2333.
24. Bolard A, Plesiat P, Jeannot K. 2017. Mutations in gene fusA1 as a novel
mechanism of aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 62:e01835-17. https://doi
.org/10.1128/AAC.01835-17.
25. Krause KM, Serio AW, Kane TR, Connolly LE. 2016. Aminoglycosides: an
overview. Cold Spring Harb Perspect Med 6:a027029. https://doi.org/10
.1101/cshperspect.a027029.
26. Wistrand-Yuen E, Knopp M, Hjort K, Koskiniemi S, Berg OG, Andersson DI.
2018. Evolution of high-level resistance during low-level antibiotic exposure. Nat Commun 9:1599. https://doi.org/10.1038/s41467-018-04059-1.
27. MacLean RC, Buckling A. 2009. The distribution of ﬁtness effects of
beneﬁcial mutations in Pseudomonas aeruginosa. PLoS Genet
5:e1000406. https://doi.org/10.1371/journal.pgen.1000406.
28. Knopp M, Andersson DI. 2018. Predictable phenotypes of antibiotic
resistance mutations. mBio 9:e00770-18. https://doi.org/10.1128/mBio
.00770-18.
29. Traverse CC, Mayo-Smith LM, Poltak SR, Cooper VS. 2013. Tangled bank
of experimentally evolved Burkholderia bioﬁlms reﬂects selection during
chronic infections. Proc Natl Acad Sci U S A 110:E250 –E259. https://doi
.org/10.1073/pnas.1207025110.
30. Turner CB, Marshall CW, Cooper VS. 2018. Parallel genetic adaptation
across environments differing in mode of growth or resource availability.
Evol Lett 2:355–367. https://doi.org/10.1002/evl3.75.
31. Trampari E, Holden ER, Wickham GJ, Ravi A, Prischi F, de Oliveira Martins
L, Savva GM, Bavro VN, Webber MA. 2019. Antibiotics select for novel
pathways of resistance in bioﬁlms. bioRxiv https://doi.org/10.1101/
605212.
32. Clinical and Laboratory Standards Institute. 2019. Performance standards
for antimicrobial susceptibility testing. Clinical and Laboratory Standards
Institute, Wayne, PA.
33. Schurek KN, Marr AK, Taylor PK, Wiegand I, Semenec L, Khaira BK,
Hancock R. 2008. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:4213– 4219. https://doi.org/10.1128/AAC.00507-08.
34. Desai MM, Fisher DS. 2007. Beneﬁcial mutation-selection balance and
the effect of linkage on positive selection. Genetics 176:1759 –1798.
https://doi.org/10.1534/genetics.106.067678.
35. Savelsbergh A, Rodnina MV, Wintermeyer W. 2009. Distinct functions of
elongation factor G in ribosome recycling and translocation. RNA 15:
772–780. https://doi.org/10.1261/rna.1592509.
36. Palmer SO, Rangel EY, Hu Y, Tran AT, Bullard JM. 2013. Two homologous
EF-G proteins from Pseudomonas aeruginosa exhibit distinct functions.
PLoS One 8:e80252. https://doi.org/10.1371/journal.pone.0080252.
37. Sanz-García F, Hernando-Amado S, Martínez JL. 2018. Mutational evolution of Pseudomonas aeruginosa resistance to ribosome-targeting antibiotics. Front Genet 9:451. https://doi.org/10.3389/fgene.2018.00451.
38. Johanson U, Hughes D. 1994. Fusidic acid-resistant mutants deﬁne three
regions in elongation factor G of Salmonella typhimurium. Gene 143:
55–59. https://doi.org/10.1016/0378-1119(94)90604-1.
39. Jones AK, Woods AL, Takeoka KT, Shen X, Wei J-R, Caughlan RE, Dean CR.
2017. Determinants of antibacterial spectrum and resistance potential of
the elongation factor G inhibitor argyrin B in key Gram-negative pathogens. Antimicrob Agents Chemother 61:e02400-16. https://doi.org/10
.1128/AAC.02400-16.
40. Gebhardt MJ, Shuman HA. 2017. GigA and GigB are master regulators of
antibiotic resistance, stress responses, and virulence in Acinetobacter baumannii. J Bacteriol 199:e00066-17. https://doi.org/10.1128/JB.00066-17.
41. Mah TF, O’Toole GA. 2001. Mechanisms of bioﬁlm resistance to antimicrobial agents. Trends Microbiol 9:34 –39. https://doi.org/10.1016/S0966
-842X(00)01913-2.
42. Burrows LL, Charter DF, Lam JS. 1996. Molecular characterization of the
Pseudomonas aeruginosa serotype O5 (PAO1) B-band lipopolysaccharide gene cluster. Mol Microbiol 22:481– 495. https://doi.org/10.1046/j
.1365-2958.1996.1351503.x.
43. Rocchetta HL, Burrows LL, Lam JS. 1999. Genetics of O-antigen biosynMay/June 2020 Volume 11 Issue 3 e00932-20

44.

45.

46.

47.

48.

49.

50.

51.

52.

53.

54.

55.

56.

57.

58.

59.

60.

thesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev 63:523–553.
https://doi.org/10.1128/MMBR.63.3.523-553.1999.
Tognon M, Köhler T, Gdaniec BG, Hao Y, Lam JS, Beaume M, Luscher A,
Buckling A, van Delden C. 2017. Co-evolution with Staphylococcus
aureus leads to lipopolysaccharide alterations in Pseudomonas aeruginosa. ISME J 11:2233–2243. https://doi.org/10.1038/ismej.2017.83.
Bryan LE, O’Hara K, Wong S. 1984. Lipopolysaccharide changes in
impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 26:250 –255. https://doi.org/10
.1128/aac.26.2.250.
Kadurugamuwa JL, Lam JS, Beveridge TJ. 1993. Interaction of gentamicin
with the A band and B band lipopolysaccharides of Pseudomonas
aeruginosa and its possible lethal effect. Antimicrob Agents Chemother
37:715–721. https://doi.org/10.1128/aac.37.4.715.
Bryan LE, Kwan S. 1983. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and
gentamicin. Antimicrob Agents Chemother 23:835– 845. https://doi.org/
10.1128/aac.23.6.835.
Damper PD, Epstein W. 1981. Role of the membrane potential in bacterial resistance to aminoglycoside antibiotics. Antimicrob Agents Chemother 20:803– 808. https://doi.org/10.1128/aac.20.6.803.
Jahn LJ, Munck C, Ellabaan MMH, Sommer M. 2017. Adaptive laboratory
evolution of antibiotic resistance using different selection regimes lead
to similar phenotypes and genotypes. Front Microbiol 8:816. https://doi
.org/10.3389/fmicb.2017.00816.
Kim S, Lieberman TD, Kishony R. 2014. Alternating antibiotic treatments
constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci
U S A 111:14494 –14499. https://doi.org/10.1073/pnas.1409800111.
Mogre A, Sengupta T, Veetil RT, Ravi P, Seshasayee A. 2014. Genomic
analysis reveals distinct concentration-dependent evolutionary trajectories for antibiotic resistance in Escherichia coli. DNA Res 21:711–726.
https://doi.org/10.1093/dnares/dsu032.
Norström T, Lannergård J, Hughes D. 2007. Genetic and phenotypic
identiﬁcation of fusidic acid-resistant mutants with the small-colonyvariant phenotype in Staphylococcus aureus. Antimicrob Agents Chemother 51:4438 – 4446. https://doi.org/10.1128/AAC.00328-07.
Gil R, Silva FJ, Peretó J, Moya A. 2004. Determination of the core of a
minimal bacterial gene set. Microbiol Mol Biol Rev 68:518 –537. https://
doi.org/10.1128/MMBR.68.3.518-537.2004.
Poulsen BE, Yang R, Clatworthy AE, White T, Osmulski SJ, Li L, Penaranda
C, Lander ES, Shoresh N, Hung DT. 2019. Deﬁning the core essential
genome of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 116:
10072–10080. https://doi.org/10.1073/pnas.1900570116.
Wattam AR, Davis JJ, Assaf R, Boisvert S, Brettin T, Bun C, Conrad N,
Dietrich EM, Disz T, Gabbard JL, Gerdes S, Henry CS, Kenyon RW, Machi
D, Mao C, Nordberg EK, Olsen GJ, Murphy-Olson DE, Olson R, Overbeek
R, Parrello B, Pusch GD, Shukla M, Vonstein V, Warren A, Xia F, Yoo H,
Stevens RL. 2017. Improvements to PATRIC, the all-bacterial Bioinformatics Database and Analysis Resource Center. Nucleic Acids Res 45:
D535–D542. https://doi.org/10.1093/nar/gkw1017.
Nyfeler B, Hoepfner D, Palestrant D, Kirby CA, Whitehead L, Yu R, Deng
G, Caughlan RE, Woods AL, Jones AK, Barnes SW, Walker JR, Gaulis S,
Hauy E, Brachmann SM, Krastel P, Studer C, Riedl R, Estoppey D, Aust T,
Movva NR, Wang Z, Salcius M, Michaud GA, McAllister G, Murphy LO,
Tallarico JA, Wilson CJ, Dean CR. 2012. Identiﬁcation of elongation factor
G as the conserved cellular target of argyrin B. PLoS One 7:e42657.
https://doi.org/10.1371/journal.pone.0042657.
Chung JCS, Becq J, Fraser L, Schulz-Trieglaff O, Bond NJ, Foweraker J,
Bruce KD, Smith GP, Welch M. 2012. Genomic variation among contemporary Pseudomonas aeruginosa isolates from chronically infected cystic
ﬁbrosis patients. J Bacteriol 194:4857– 4866. https://doi.org/10.1128/JB
.01050-12.
López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA,
Johansen HK, Figuerola J, Cantón R, Kidd TJ, Molin S, Oliver A. 2017.
Evolution of the Pseudomonas aeruginosa mutational resistome in an
international cystic ﬁbrosis clone. Sci Rep 7:5555. https://doi.org/10
.1038/s41598-017-05621-5.
López-Causapé C, Rubio R, Cabot G, Oliver A. 2018. Evolution of the
Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro
and in the cystic ﬁbrosis setting. Antimicrob Agents Chemother 62:
e02583-17. https://doi.org/10.1128/AAC.02583-17.
Markussen T, Marvig RL, Gómez-Lozano M, Aanæs K, Burleigh AE, Høiby
N, Johansen HK, Molin S, Jelsbak L. 2014. Environmental heterogeneity
mbio.asm.org 16

Downloaded from https://journals.asm.org/journal/mbio on 23 July 2021 by 134.48.159.153.

®

Scribner et al.

61.

62.
63.

64.

65.

66.

67.

68.

69.

70.

71.

drives within-host diversiﬁcation and evolution of Pseudomonas aeruginosa. mBio 5:e01592-14. https://doi.org/10.1128/mBio.01592-14.
Brockhurst MA, Harrison F, Veening J-W, Harrison E, Blackwell G, Iqbal Z,
Maclean C. 2019. Assessing evolutionary risks of resistance for new
antimicrobial therapies. Nat Ecol Evol 3:515–517. https://doi.org/10
.1038/s41559-019-0854-x.
MacLean RC, San Millan A. 2019. The evolution of antibiotic resistance.
Science 365:1082–1083. https://doi.org/10.1126/science.aax3879.
Gruger T, Nitiss JL, Maxwell A, Zechiedrich EL, Heisig P, Seeber S,
Pommier Y, Strumberg D. 2004. A mutation in Escherichia coli DNA
gyrase conferring quinolone resistance results in sensitivity to drugs
targeting eukaryotic topoisomerase II. Antimicrob Agents Chemother
48:4495– 4504. https://doi.org/10.1128/AAC.48.12.4495-4504.2004.
Qi Q, Preston GM, MacLean RC. 2014. Linking system-wide impacts of
RNA polymerase mutations to the ﬁtness cost of rifampin resistance in
Pseudomonas aeruginosa. mBio 5:e01562-14. https://doi.org/10.1128/
mBio.01562-14.
Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma
JJ, Ranganathan SC, Waters VJ, Ratjen FA. 2014. Antibiotic management
of lung infections in cystic ﬁbrosis. I. The microbiome, methicillinresistant Staphylococcus aureus, Gram-negative bacteria, and multiple
infections. Ann Am Thorac Soc 11:1120 –1129. https://doi.org/10.1513/
AnnalsATS.201402-050AS.
McCall IC, Shah N, Govindan A, Baquero F, Levin BR. 2019. Antibiotic
killing of diversely generated populations of nonreplicating bacteria.
Antimicrob Agents Chemother 63:e02360-18. https://doi.org/10.1128/
AAC.02360-18.
Dettman JR, Sztepanacz JL, Kassen R. 2016. The properties of spontaneous mutations in the opportunistic pathogen Pseudomonas aeruginosa.
BMC Genomics 17:27. https://doi.org/10.1186/s12864-015-2244-3.
Long H, Sung W, Miller SF, Ackerman MS, Doak TG, Lynch M. 2014.
Mutation rate, spectrum, topology, and context-dependency in the DNA
mismatch repair-deﬁcient Pseudomonas ﬂuorescens ATCC948. Genome
Biol Evol 7:262–271. https://doi.org/10.1093/gbe/evu284.
Breen MS, Kemena C, Vlasov PK, Notredame C, Kondrashov FA. 2012.
Epistasis as the primary factor in molecular evolution. Nature 490:
535–538. https://doi.org/10.1038/nature11510.
Hernando-Amado S, Sanz-García F, Martínez JL. 2019. Antibiotic resistance evolution is contingent on the quorum-sensing response in Pseudomonas aeruginosa. Mol Biol Evol 36:2238 –2251. https://doi.org/10
.1093/molbev/msz144.
MacLean RC, Perron GG, Gardner A. 2010. Diminishing returns from
beneﬁcial mutations and pervasive epistasis shape the ﬁtness landscape
for rifampicin resistance in Pseudomonas aeruginosa. Genetics 186:
1345–1354. https://doi.org/10.1534/genetics.110.123083.

May/June 2020 Volume 11 Issue 3 e00932-20

72. Ward H, Perron GG, Maclean RC. 2009. The cost of multiple drug
resistance in Pseudomonas aeruginosa. J Evol Biol 22:997–1003. https://
doi.org/10.1111/j.1420-9101.2009.01712.x.
73. Kryazhimskiy S, Rice DP, Jerison ER, Desai MM. 2014. Global epistasis
makes adaptation predictable despite sequence-level stochasticity. Science 344:1519 –1522. https://doi.org/10.1126/science.1250939.
74. Papp B, Notebaart RA, Pál C. 2011. Systems-biology approaches for
predicting genomic evolution. Nat Rev Genet 12:591– 602. https://doi
.org/10.1038/nrg3033.
75. Baumann P, Doudoroff M, Stanier RY. 1968. Study of the Moraxella group
I. Genus Moraxella and the Neisseria catarrhalis group. J Bacteriol 95:
58 –73. https://doi.org/10.1128/JB.95.1.58-73.1968.
76. Piechaud M, Second L. 1951. Studies of 26 strains of Moraxella iwofﬁ.
Ann Inst Pasteur (Paris) 80:97–99.
77. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM.
1995. Common virulence factors for bacterial pathogenicity in plants
and animals. Science 268:1899 –1902. https://doi.org/10.1126/science
.7604262.
78. Palmer KL, Aye LM, Whiteley M. 2007. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic ﬁbrosis sputum. J
Bacteriol 189:8079 – 8087. https://doi.org/10.1128/JB.01138-07.
79. Poltak SR, Cooper VS. 2011. Ecological succession in long-term experimentally evolved bioﬁlms produces synergistic communities. ISME J
5:369 –378. https://doi.org/10.1038/ismej.2010.136.
80. O’Toole GA. 2011. Microtiter dish bioﬁlm formation assay. J Vis Exp
2011:2437. https://doi.org/10.3791/2437.
81. Baym M, Kryazhimskiy S, Lieberman TD, Chung H, Desai MM, Kishony R.
2015. Inexpensive multiplexed library preparation for megabase-sized
genomes. PLoS One 10:e0128036. https://doi.org/10.1371/journal.pone
.0128036.
82. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a ﬂexible trimmer for
Illumina sequence data. Bioinformatics 30:2114 –2120. https://doi.org/10
.1093/bioinformatics/btu170.
83. Deatherage DE, Barrick JE. 2014. Identiﬁcation of mutations in
laboratory-evolved microbes from next-generation sequencing data using breseq. Methods Mol Biol 1151:165–188. https://doi.org/10.1007/978
-1-4939-0554-6_12.
84. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H,
Shindyalov IN, Bourne PE. 2000. The Protein Data Bank. Nucleic Acids Res
28:235–242. https://doi.org/10.1093/nar/28.1.235.
85. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng
EC, Ferrin TE. 2004. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612. https://doi
.org/10.1002/jcc.20084.

mbio.asm.org 17

Downloaded from https://journals.asm.org/journal/mbio on 23 July 2021 by 134.48.159.153.

®

Parallel Evolution of Antibiotic Resistance

